Ribometrix Inc., a Durham, N.C.-based startup developing small-molecule drugs to modulate RNA activity, has raised $30 million in a series A financing. The round, led by Merck KGaA's M Ventures, will help the company advance its discovery platform and its internal pipeline, it said.